(19)
(11) EP 1 235 793 A2

(12)

(88) Date of publication A3:
10.01.2002

(43) Date of publication:
04.09.2002 Bulletin 2002/36

(21) Application number: 00990650.4

(22) Date of filing: 05.12.2000
(51) International Patent Classification (IPC)7: C07C 275/38, C07D 295/13, A61K 31/5375, A61K 31/17, A61P 27/02
(86) International application number:
PCT/EP0012/226
(87) International publication number:
WO 0104/2192 (14.06.2001 Gazette 2001/24)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 07.12.1999 US 455670

(71) Applicants:
  • Novartis AG
    4056 Basel (CH)

    BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR 
  • Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
    1230 Wien (AT)

    AT 

(72) Inventors:
  • WATTANASIN, Sompong
    Hopatcong, NJ 07832 (US)
  • WEIDMANN, Beat
    Chatham, NJ 07928 (US)

   


(54) VLA-4 INTEGRIN ANTAGONISTS